Clinical trials sponsored by Chongqing Precision Biotech Co., Ltd

Phase breakdown

Conditions studied

Recruiting trials led by Chongqing Precision Biotech Co., Ltd

• A Clinical Trial Targeting CEA Chimeric Antigen Receptor T (CAR-T) for CEA Positive Advanced Malignant Solid Tumors
  NCT06043466 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 4 locations
• A Clinical Trial of CEA Targeting CAR-T for CEA Positive Advanced Lung Cancer
  NCT06768151 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Anti-CEA CAR-T for Advanced CEA-Positive Lung Carcinoma
  NCT06903117 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• CD70-Targeted CAR-T Therapy in CD70-Positive Advanced Solid Tumors
  NCT07181720 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
  NCT06006390 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 12 locations
• CEA-Targeted CAR-T Therapy in CEA-Positive Advanced Solid Tumors
  NCT07179692 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Clinical Study of CEA Targeting Chimeric Antigen Receptor T Lymphocytes（CAR-T） for CEA Positive Advanced Malignant Solid Tumors
  NCT06126406 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors
  NCT06010862 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• Clinical Trial of CD19 Targeted CAR-T Cell in Refractory Adult SLE
  NCT06892145 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• Safety and Efficacy of CD19 Targeted CAR-T Therapy for Refractory Autoimmune Disease
  NCT06056921 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• Study of CD19 CAR-T Therapy for Refractory SLE
  NCT07403097 · Phase: Phase 1 · Ages: 5 Years and older · Sex: All (male and female) · 1 location
• Study of Ultra-Fast BCMA/CD70 CAR-T Therapy for Refractory SLE
  NCT07318259 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Study of Ultra-Fast CD19 CAR-T Therapy for Refractory SLE
  NCT07331467 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Targeted Anti-CEA CAR-T Immunotherapy for Advanced Lung Cancer
  NCT06992583 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 1 location

Common questions

How many trials is Chongqing Precision Biotech Co., Ltd recruiting for?

Chongqing Precision Biotech Co., Ltd is the lead sponsor of 14 recruiting trials.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.